MedTrace Logo

Treatment Of Patients With Social Anxiety Disorder

NCT00397722 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 299

Last updated 2017-07-11

No results posted yet for this study

Summary

GW876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with SocAD experience in social situations.

Conditions

  • Social Phobia

Interventions

DRUG

GW876008

DRUG

paroxetine

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-09
Primary Completion
2007-09-05
Completion
2007-09-05

Countries

  • United States
  • Canada
  • Finland
  • Germany
  • Norway
  • South Africa
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00397722 on ClinicalTrials.gov